Estudo randomizado | Dose única de uma nova vacina vetorizada de adenovírus tipo 5 contra o SARS-CoV-2 mostrou-se segura e teve eficácia de 57,5% contra Covid-19 sintomática e de 91,7% contra doença grave em adultos.

Final efficacy analysis, interim safety analysis, and immunogenicity of a single dose of recombinant novel coronavirus vaccine in adults 18 years and older: an international, multicentre, randomised, double-blinded, placebo-controlled phase 3 trial – The Lancet

Comentários:

Efficacy of an adenovirus type 5 vectored SARS-CoV-2 vaccine – The Lancet

Phase 3 trial reports one dose of Ad5-nCoV COVID-19 vaccine is safe and effective, including against severe disease – The Lancet